Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories ABT, -1.10% said Tuesday it plans to restart manufacturing formula at its plant in Sturgis, Mich., on June 4, and it will prioritize production of EleCare, a hypoallergenic, amino acid-based formula.

Abbott to restart production of EleCare formula on June 4

Abbott to release limited quantities of EleCare® branded specialty formulas Product will be released immediately free of charge to children in need Parents and caregivers in urgent need should contact their healthcare professionals or Abbott at +1-800-881-0876 for additional information Abbott plans to restart production at the Sturgis facility on June 4 and will prioritize EleCare production, with initial EleCare product release to consumers beginning on or about June 20 ABBOTT PARK, Ill., May 24, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing Abbott to release limited quantities of its EleCare® specialty amino acid-based formulas that were previously on hold following the Feb. 17 recall of some powder infant formulas from its Sturgis, Mich.

Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need

Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.

Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable

Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the nationwide shortage of baby formula and promised production will ramp up again in June.

The Wall Street Journal: Abbott CEO apologizes for baby formula shortage, promises production ramp-up

The apology by Abbott's CEO came after President Joe Biden signed a new law to deal with the baby formula shortage.

'We're sorry' for U.S. baby formula shortage, Abbott CEO Ford says in Washington Post op-ed

There are more stormy waters ahead, but they might not be a problem in the end.

What Could the Baby Formula Shortage Mean for Abbott Laboratories?

Abbott is dealing with some significant pressure due to the baby formula shortage. The shares of Abbott are trading for a price 22% lower than the 52 weeks high.

Abbott Is A Great Company, But Its Price Makes It Unattractive

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Down 8.9% Since Last Earnings Report: Can It Rebound?

Abbott Laboratories' India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday.

Abbott completes India recall of baby formula products imported from U.S

Economists condemn ‘rot' in system after manufacturer issued billions in stock buybacks despite problems at Michigan factory

Abbott enriched shareholders as faulty plant needed repairs, records show

Abbott Laboratories and the U.S. Food and Drug Administration are on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said on Thursday.

Abbott baby formula plant on track to reopen within 1-2 weeks -FDA commissioner

Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system.

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

At one time, a factory in Denmark run by pharmaceutical firm Novo Nordisk A/S (ADR: NVO) made half of the world's supply of insulin. Vowing to never run short of a product that people's lives depended upon, Novo kept a five-year supply in the deep freeze.

What price will the supply chain pay for resiliency?

Senate Finance Committee Chair Ron Wyden sent a letter to Abbott CEO Robert Ford requesting information on the company's tax practices and $8 billion stock buybacks the company has authorized since 2019.

Senate panel investigates Abbott tax practices after contamination shut down baby formula plant

ABT stock is climbing on reports that Abbott has reached a deal to restart baby formula production at its Sturgis, Michigan plant. The post ABT Stock Climbs as Abbott Reaches a Baby Formula Deal With the FDA appeared first on InvestorPlace.

ABT Stock Climbs as Abbott Reaches a Baby Formula Deal With the FDA

Big losses in the company's offerings for tiny people might not be as bad as they seem.

How the Infant Formula Recall Will Impact Abbott's Revenue

Abbott said it could reopen its factory within two weeks, and then it would take six to eight more weeks for the products to reach stores.

FDA and Abbott Nutrition reach deal to restart production of baby formula amid nationwide shortage

It could take more than 10 weeks for Abbott Laboratories' baby formula to reappear on store shelves, the company said.

Abbott Strikes Deal With FDA To Reopen Baby Formula Plant At Center Of National Shortage

Abbott Laboratories and the Food and Drug Administration reached a deal Monday to restart production of baby formula at a U.S. plant that has been shut down amid a recall of the product, which contributed to a nationwide shortage of formula.

Abbott, FDA reach deal to resume making baby formula at U.S. plant amid shortage

Under a consent decree, Abbott has agreed to address insanitary conditions that led to the contamination of its baby formula plant in Sturgis, Michigan.

Abbott reaches agreement with FDA to reopen baby formula plant to ease nationwide shortage

After FDA approval, Abbott could restart the site within two weeks; from the time of restart it would take six to eight weeks before product is available on shelves Abbott will continue to import formula from FDA-registered facility in Ireland to help alleviate near-term supply shortage CDC concluded its investigation with no findings of a link between Abbott formulas and infant illnesses ABBOTT PARK, Ill., May 16, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich.

Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

Abbott Laboratories, the biggest U.S. supplier of powder infant formula including Similac, initiated a recall and closed its Sturgis, Michigan, manufacturing plant earlier this year after reports of serious bacterial infections in four infants.

Explainer-What happened with Abbott baby formula that worsened a U.S. shortage?

Abbott Laboratories has turned to air cargo to help overcome a domestic shortage of infant formula exacerbated by a February recall due to suspected contamination and the subsequent shutdown of its Sturgis, Michigan, plant.  The beleaguered maker of Similac and other formula brands said Friday it is taking a number of steps to alleviate formula supply problems, with a focus on increasing production at its Cootehill, Ireland, facility.

Abbott ramps up air cargo imports of infant formula

A recall of products produced at Abbott's Sturgis, Michigan facility has contributed to a nationwide shortage of baby formula.

Abbott says if the FDA were to re-open its Michigan facility to address baby formula shortage, it would still take months to get more on shelves

Abbott Nutrition said Friday it has bolstered production at its baby formula manufacturing plants in Ireland and Michigan in an effort to ease the shortages exacerbated by the shutdown of its

News for Abbott Labs Stock (ABT)